Eligibility Criteria
impaired liver function, anemia
GASTROINTESTINAL STROMAL TUMOR (GIST), ANEMIA, IMPAIRED RENAL FUNCTION
For phase I, enrollment criteria were surgically unresectable or metastatic gastrointestinal stromal tumor (GIST) confirmed by histology or cytology, and either progression after treatment with imatinib and at least one other tyrosine kinase inhibitor (TKI) or intolerance to standard of care (SOC) or lack of available SOC, or presence of a mutation in the platelet-derived growth factor receptor alpha (Patients were excluded from the study if, within 14 days prior to the first administration of the study drug, they had received antineoplastic drugs, received neutrophil growth factor support, received a potent inhibitor of cytochrome P450 3A4 or a potent or intermediate induction agent, or undergone surgery. Exclusion criteria also included impaired liver function tests, impaired renal function based on creatinine clearance, low platelet or neutrophil counts, and anemia (hemoglobin <9 g/dL).